Theravance Biopharma, Inc. (TBPH) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 30.77M USD | Liabilities, Current |
| Cash and equivalents | 219.77M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 167.89M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $30.77M | $219.77M | $167.89M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $31.77M | $288.10M | $106.56M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $38.30M | $167.81M | $147.55M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $37.41M | $174.77M | $154.91M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $54.63M | $281.93M | $56.88M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $31.50M | $110.61M | $20.24M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $32.09M | $37.80M | $50.55M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $23.43M | $23.38M | $67.98M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $22.95M | $46.34M | $49.73M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $21.66M | $53.84M | $46.14M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $24.77M | $39.55M | $62.88M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $25.37M | $71.69M | $62.32M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $24.55M | $105.60M | $61.85M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $26.18M | $187.66M | $53.60M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $28.71M | $298.17M | $29.31M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $142.13M | $418.54M | $68.29M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $32.62M | $87.29M | $45.56M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $44.20M | $94.37M | $53.15M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $58.59M | $89.96M | $83.51M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $66.08M | $121.42M | $94.79M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $67.13M | $204.95M | $60.00M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $86.49M | $114.01M | $95.96M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $123.57M | $81.47M | $211.47M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $104.27M | $93.28M | $265.06M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $106.57M | $104.73M | $333.61M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $98.04M | $332.80M | $154.23M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $111.70M | $58.06M | $222.77M | (m) | (m) | (m) |
| 2019-09-30 | $319.77M | $108.82M | $102.40M | $217.28M | $87.00K | (m) | 2.94× |
| 2019-06-30 | $396.18M | $110.14M | $178.31M | $217.76M | $111.00K | (m) | 3.60× |
| 2019-03-31 | $434.17M | $113.54M | $223.24M | $210.82M | $113.00K | (m) | 3.82× |
| 2018-12-31 | $505.90M | $98.55M | $378.02M | $127.25M | $620.00K | $0.00 | 5.13× |
| 2018-09-30 | $303.43M | $102.03M | $101.20M | $199.21M | $3.02M | $17.92M | 2.97× |
| 2018-06-30 | $356.34M | $93.48M | $103.85M | $249.05M | $3.43M | $17.91M | 3.81× |
| 2018-03-31 | $420.50M | $105.18M | $125.83M | $292.70M | $1.97M | $17.22M | 4.00× |
| 2017-12-31 | $350.82M | $62.55M | $88.98M | $259.59M | $2.25M | $16.83M | 5.61× |
| 2017-09-30 | $336.58M | $48.79M | $91.30M | $243.70M | $1.58M | $15.26M | 6.90× |
| 2017-06-30 | $363.17M | $57.10M | $139.63M | $222.19M | $1.35M | $12.13M | 6.36× |
| 2017-03-31 | $394.00M | $48.98M | $169.94M | $222.82M | $1.23M | $13.21M | 8.04× |
| 2016-12-31 | $501.74M | $49.27M | $344.71M | $156.39M | $646.00K | $12.22M | 10.18× |
| 2016-09-30 | $231.35M | $45.41M | $86.57M | $143.91M | $873.00K | $12.48M | 5.09× |
| 2016-06-30 | $251.53M | $44.66M | $148.36M | $101.32M | $1.86M | $9.81M | 5.63× |
| 2016-03-31 | $181.40M | $46.40M | $128.80M | $51.07M | $1.53M | $9.41M | 3.91× |
| 2015-12-31 | $174.36M | $49.47M | $112.71M | $59.73M | $1.92M | $10.01M | 3.52× |
| 2015-09-30 | $196.75M | $27.43M | $127.11M | $68.86M | $783.00K | $12.14M | 7.17× |
| 2015-06-30 | $211.79M | $24.48M | $97.09M | $113.90M | $805.00K | $12.55M | 8.65× |
| 2015-03-31 | $236.80M | $28.85M | $100.90M | $135.34M | $565.00K | $12.34M | 8.21× |
| 2014-12-31 | $254.90M | $41.26M | $89.22M | $165.40M | $289.00K | $12.55M | 6.18× |
| 2014-09-30 | $284.95M | $35.83M | $122.23M | $162.49M | $230.00K | $15.13M | 7.95× |
| 2014-06-30 | $349.29M | $40.11M | $268.20M | $81.00M | $90.00K | $14.76M | 8.71× |
| 2014-06-02 | (m) | (m) | $277.54M | (m) | $125.00K | $14.33M | (m) |
| 2014-03-31 | (m) | $38.54M | $0.00 | (m) | $3.00K | $11.01M | (m) |
| 2013-12-31 | (m) | $36.85M | $0.00 | (m) | $199.00K | $10.41M | (m) |
| 2013-09-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |